Taysha Gene Therapies received a notice of noncompliance with Nasdaq's minimum bid price requirement, has 180 days to regain compliance, and may be eligible for an additional 180-day compliance period if it transfers to The Nasdaq Capital Market. Kathleen Reape has resigned from the Board of Directors, and the Board will be reconstituted.